{"schema_version":"secwatch.filing_event.v1","accession":"0001099800-22-000023","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.603170+00:00","generated_at":"2026-06-22T23:30:49.879497+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Edwards Q3 sales $1.32B; adjusted EPS $0.61 (up 13% YoY); cuts FY22 adjusted EPS guidance to $2.40-$2.50","bullets":["GAAP EPS $0.55, adjusted EPS $0.61; $0.07/share charge from discontinuing HARPOON surgical mitral repair.","TAVR sales $862M (+1% reported, +6% cc); TMTT sales $30M; U.S. procedures grew mid-single digits YoY.","2022 adjusted EPS guidance revised to $2.40-$2.50 from prior $2.50-$2.65 range; total sales now expected at low end of $5.35-$5.55B.","Received U.S. FDA and CE Mark for PASCAL Precision; U.S. FDA approval for SAPIEN 3 Ultra RESILIA valve.","Q3 free cash flow $250M; cash and investments $1.7B as of Sept. 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001099800-22-000023","json":"https://secwatch.observer/filing/0001099800-22-000023.json","markdown":"https://secwatch.observer/filing/0001099800-22-000023.md","text":"https://secwatch.observer/filing/0001099800-22-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/0001099800-22-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/ew-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T23:30:49.879497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3d5b3f22327a796e65730f745e235136552bf5f7","claim":"Edwards Lifesciences Corp updated its quarter ended September 30, 2022 guidance (lowered).","evidence_excerpt":"On October 27, 2022, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000109980022000023/0001099800-22-000023-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}